Gangestad Nicholas C

Director Nicholas C Gangestad purchased 2,000 shares of AMRZ at $47.34; holdings increased 67.6% to 4,958 shares post-transaction.

Gangestad acquired 2,000 shares for $94,680.00, raising his holdings from 2,958 shares to 4,958 shares (+67.6% increase in his position). The purchase occurred at $47.34 against a current market price of $47.14, placing the transaction near current levels but 15.3% below the 52-week high of $55.63. Across his open-market history (2 prior buys, 2 prior sells), Gangestad's buy timing has shown mixed results: 30-day returns averaging -3.3% and 90-day returns averaging 2.9% with a 50% win rate, while his sell timing has been more consistently well-timed with a 100% well-timed rate at the 90-day horizon. The company reported $3.7B in revenue and $545.0M in net income in its latest quarter, with a $26.1B market cap, providing fundamental context for a $94.7K buy by a director.

Director Nicholas C Gangestad purchases 2,000 shares of Genpact (G) at $43.97; stock down 22.2% from 52-week high.

Nicholas C Gangestad, a Director, acquired 2,000 shares at $43.97 on 2025-05-13, establishing his first holding in the company. The purchase occurs with Genpact stock trading 22.2% below its 52-week high of $55.54 and down 10.0% over the prior 30 days. Gangestad's cross-ticker track record shows mixed timing: 1 prior buy averaged -5.8% return at 30 days but +7.5% at 90 days with a 100% win rate, while 2 prior sells were well-timed 100% of the time. Genpact remains fundamentally sound with a 14.31 P/E, recent quarterly revenue of $1,214,926,000.00, and net income of $130,853,000.00, though annual revenue growth of 6.5% is modest. The timing and modest scale of this initial purchase warrant observation in the context of recent price weakness.